Q-omics provides the consensus-scored XPNPEP2 profile across patient tissues and cancer cell-line models. XPNPEP2 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, XPNPEP2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, XPNPEP2 protein abundance shows 22,047 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, KIRC, and GBM as cancer lineages where XPNPEP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for XPNPEP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes XPNPEP2 survival associations across molecular data types. XPNPEP2 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (10) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible XPNPEP2 RNA expression–survival associations across cancer types. High XPNPEP2 expression shows unfavorable associations in BLCA, LGG, CESC and OV, but favorable associations in LUAD and DLBC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify BLCA as the clearest survival context for XPNPEP2 RNA expression.
This table summarizes XPNPEP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for XPNPEP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. XPNPEP2 shows lower tumor expression in KIRC, KIRP, BLCA, KICH, HNSC and THCA. The KIRC box plot shows higher XPNPEP2 RNA expression in normal versus tumor tissue (log2 FC = −4.149, t-test p < 0.001).
This table shows molecular features associated with XPNPEP2 in patient tissues and cancer cell lines. In patient samples, XPNPEP2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, XPNPEP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
